Lesson
Start With the Fungal Cell
Fungi are eukaryotes with a membrane, cell wall, and biologic forms that create a smaller therapeutic margin and a different diagnostic vocabulary from bacteria.
- Ergosterol
- Beta glucan
- Yeast
- Mold
- Dimorphism
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Map selective targets
Ergosterol in the fungal membrane and beta glucan in many fungal cell walls create therapeutic targets. Eukaryotic overlap also explains why systemic antifungals can injure human organs.
Separate yeast from mold
Yeasts are unicellular and can colonize mucosa or invade sterile sites. Molds grow hyphae and include Aspergillus, Mucorales, Fusarium, and other filamentous fungi with distinct spectra.
Use dimorphism as ecology
Several endemic fungi change morphology with temperature and tissue environment. Geography, travel, soil exposure, and host immunity can remain relevant long after exposure.
Do not mistake classification for diagnosis
A morphology narrows the problem but does not prove invasion, species, susceptibility, or site. Tissue, culture, molecular, and clinical evidence complete the model.
Quick check
Lesson
Separate Presence From Disease
A fungus can be a colonizer, contaminant, mucosal pathogen, or invasive organism. Host defense and anatomic breach determine which state matters.
- Colonization
- Neutropenia
- T cells
- Devices
- C auris
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Read the host defect
Neutropenia, transplant, corticosteroids, T-cell deficits, mucosal injury, surgery, critical illness, and invasive devices create different pathogen and compartment risks.
Interrogate the specimen site
Candida from blood has different meaning from Candida in respiratory secretions. Nonsterile-site recovery does not by itself establish tissue invasion.
Treat the source
Central lines, prosthetic material, obstruction, necrosis, abscesses, and devitalized tissue can sustain infection. Removal, drainage, debridement, or surgery can be as important as the drug.
Keep C auris states distinct
Candidozyma auris can colonize skin for prolonged periods and spread in healthcare facilities. Screening guides infection control. Only clinical infection receives antifungal treatment.
Quick check
Lesson
Make Every Test Answer a Question
Fungal evidence is distributed across culture, tissue, biomarkers, molecular assays, imaging, and host probability. No single result replaces the clinical model.
- Culture
- Histopathology
- Beta glucan
- Galactomannan
- Molecular testing
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Start with specimen quality
Blood culture remains central for candidemia but misses many deep or mold infections. Tissue, sterile fluid, BAL, and source material may be needed according to anatomy.
Preserve culture and pathology
Tissue can show invasion and morphology while culture or molecular testing identifies the organism. Coordinate handling so all tissue is not fixed when a fresh portion is needed.
Use beta glucan as an adjunct
Beta-D-glucan can support invasive fungal disease but is not Candida-specific or Aspergillus-specific. False positives and prior antifungals change interpretation.
Target aspergillosis evidence
Selected high-risk patients use chest CT, bronchoscopy when safe, BAL culture and cytology, and galactomannan. Serum galactomannan screening performs differently during mold-active prophylaxis and across host groups.
Quick check
Lesson
Connect Drug Class to Fungal Structure
Systemic antifungals act at membrane ergosterol, ergosterol synthesis, cell-wall glucan, or nucleic-acid pathways. Target alone does not guarantee spectrum or site exposure.
- Polyenes
- Azoles
- Echinocandins
- Flucytosine
- Other targets
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Place polyenes at the membrane
Amphotericin binds ergosterol and disrupts membrane integrity. Deoxycholate, lipid complex, and liposomal products differ in dosing and toxicity and are not milligram-for-milligram substitutes.
Place azoles upstream of ergosterol
Azoles inhibit lanosterol 14 alpha demethylase. Individual agents differ in yeast and mold spectrum, metabolism, absorption, QT effects, and tissue penetration.
Place echinocandins at the wall
Caspofungin, micafungin, anidulafungin, and rezafungin inhibit beta glucan synthesis. They are major invasive Candida drugs but have important urine, eye, CNS, and bone limitations.
Protect flucytosine combination use
Flucytosine becomes active metabolites inside fungal cells and disrupts nucleic acid and protein synthesis. Rapid resistance and exposure-dependent marrow and liver toxicity prevent casual monotherapy.
Quick check
Lesson
Interpret the MIC Through a Current Standard
Species, method, drug, dose, site, and breakpoint all participate in susceptibility interpretation. A raw MIC is not a universal answer.
- Species
- MIC
- Breakpoint
- SDD
- C auris
- Resistance
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Use the current recognized standard
FDA recognizes 2026 CLSI yeast and filamentous-fungi susceptibility standards for applicable drug and organism pairs. Not every antifungal has a recognized breakpoint.
Understand SDD
Susceptible-dose dependent means efficacy relies on a regimen that reaches the higher exposure tied to that category. It is not identical to fully susceptible or resistant.
Label C auris limits honestly
Formal CLSI C auris breakpoints remain unavailable. CDC tentative breakpoints use expert opinion and related species, so response, identification, public health, and expert context remain visible.
Recognize resistance systems
ERG pathway changes, efflux, FKS mutations, biofilm, transmitted resistant strains, and environmental azole pressure can produce failure. C auris and resistant C parapsilosis require infection-control awareness.
Quick check
Lesson
Turn a Dose Into Tissue Exposure
Loading, absorption, distribution, protein binding, clearance, MIC, site, and host physiology determine whether the prescription becomes antifungal activity.
- Loading
- PK and PD
- Penetration
- TDM
- Steady state
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Preserve loading doses
Long half-life or distribution can delay effective concentrations. A required loading regimen is a distinct part of therapy, not an optional extra maintenance dose.
Choose for the compartment
CNS, urine, eye, bone, abscess, lung, and blood receive different drug exposures. An active MIC cannot compensate for inadequate delivery to the infected site.
Use TDM for a reason
Itraconazole, voriconazole, selected posaconazole uses, and flucytosine can benefit from concentration monitoring. Draw a correctly timed level and define the efficacy or toxicity action before ordering it.
Recheck after change
Dose, formulation, food, gastric pH, interacting drugs, organ function, adherence, and inflammation can alter exposure. A previously adequate concentration does not protect a changed system.
Quick check
Lesson
Treat Formulation as a Clinical Variable
Product, route, vehicle, food, pH, swallowing, renal function, and hepatic function can change exposure or toxicity before organism susceptibility matters.
- Bioavailability
- Food
- Gastric pH
- Renal function
- Hepatic function
- SBECD
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Reject dose-for-dose substitution
Posaconazole suspension and delayed-release tablets differ in bioavailability, food effects, and dosing. Itraconazole solution and capsules also have different absorption requirements.
Audit oral delivery
Meals, acid suppression, mucositis, vomiting, tube feeds, swallowing, access, and adherence can undermine an oral plan. Teach-back should include the exact product.
Separate renal mechanisms
Fluconazole and flucytosine require renal exposure adjustment. Amphotericin can injure kidneys and electrolytes. Selected IV azole vehicles can accumulate when renal function is impaired.
Follow liver trajectory
Many triazoles depend on hepatic metabolism and can cause liver injury. Product-specific adjustments, contraindications, interactions, and serial laboratory interpretation matter.
Quick check
Lesson
Map Both Sides of the Interaction
Triazoles can change other drugs and be changed by them. The interaction can begin or reverse when either agent is started, stopped, or reformulated.
- CYP
- Transporters
- Inducers
- QT
- Isavuconazole
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Map high-risk victims
Tacrolimus, cyclosporine, sirolimus, warfarin, selected anticoagulants, statins, oncology drugs, and other narrow-therapeutic-index substrates can become toxic during azole inhibition.
Map strong inducers
Rifamycins, selected anticonvulsants, St John's wort, and other inducers can collapse triazole exposure. Some combinations are contraindicated rather than manageable by routine monitoring.
Treat discontinuation as an interaction
Stopping an azole removes inhibition and can lower the exposure of a previously reduced substrate. Stopping an inducer can increase antifungal exposure as enzyme activity recovers.
Use drug-specific electrophysiology
Several azoles prolong QT, while isavuconazole can shorten QT and is contraindicated in familial short QT syndrome. Potassium, magnesium, calcium, bradycardia, and the full QT burden remain relevant.
Quick check
Lesson
Monitor the Toxicity the Drug Can Actually Cause
Kidney, electrolytes, liver, marrow, skin, vision, nervous system, heart, infusion physiology, and interacting toxins require drug-specific surveillance.
- Kidney
- Electrolytes
- Liver
- CBC
- Vision
- Infusion
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Follow amphotericin physiology
Monitor creatinine, urine output, potassium, magnesium, infusion reactions, blood counts, and nephrotoxin burden according to formulation and clinical state.
Follow azole-specific toxicity
Liver injury, QT effects, visual and neurologic symptoms, photosensitivity, skin cancer risk with prolonged voriconazole, and heart failure risk with itraconazole require agent-specific plans.
Follow flucytosine exposure
Renal accumulation can cause marrow suppression, liver injury, and gastrointestinal or neurologic toxicity. Concentration, CBC, renal function, and liver tests belong in the same loop.
Classify infusion events
Rigors, fever, flushing, rash, hypotension, bronchospasm, and anaphylaxis require timing and physiology. Rate-related symptoms and true anaphylaxis do not receive the same response.
Quick check
Lesson
Close the Loop From Empiric Therapy to Cure
Antifungal stewardship protects time to active therapy for high-risk patients while preventing indefinite empiric treatment, unsafe step-down, blind escalation, and treatment of colonization.
- Empiric
- Preemptive
- Step-down
- Source control
- Failure audit
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Connect organism, host, compartment, evidence, exposure, and ownership before selecting therapy.
Target empiric strategies
Persistent fever alone does not justify the same pathway in every patient. Neutropenia duration, host risk, prophylaxis, imaging, biomarkers, hemodynamics, and local protocols define empiric or preemptive use.
Build a safe step-down
Clinical stability, source control, culture clearance when relevant, susceptible organism, active oral option, reliable absorption, interaction management, adherence, and follow-up must align.
Audit failure before escalation
Reopen diagnosis, specimen, site, source, dose, formulation, absorption, interaction, concentration, susceptibility, resistance, immune recovery, and inflammatory timing.
Keep the educational boundary visible
These principles organize clinical reasoning. Patient-specific treatment still requires current labeling, guidelines, local susceptibility, microbiology, pharmacy, infectious diseases, and source-control expertise.
Quick check
Module test
Check the connections.
Each attempt draws 10 questions from the complete 176 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Lecture material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.